Further, GPIbα-blockade reduced cerebral damage in experimental stroke of aged and comorbid animals (e.g., atherosclerotic Ldlr−/−, diabetic or hypertensive mice) indicating that GPIbα-blockade may be a therapeutic option in the future for patients with accompanying common cardiovascular diseases (37). Here, GP1BA is linked to stroke disorder.